Tigecycline: a novel broad-spectrum antimicrobial (Q34630833)

3 August 2017

1 reference

title

Tigecycline: a novel broad-spectrum antimicrobial (English)

1 reference

3 August 2017

Christine M Slover

1

1 reference

3 August 2017

Keith A Rodvold

series ordinal

2

1 reference

3 August 2017

Larry H Danziger

series ordinal

3

1 reference

3 August 2017

language of work or name

English

0 references

publication date

22 May 2007

1 reference

Annals of Pharmacotherapy

3 August 2017

1 reference

3 August 2017

41

1 reference

3 August 2017

965-972

1 reference

3 August 2017

6

1 reference

Tigecycline: what is it, and where should it be used?

3 August 2017

1 reference

Tigecycline: a new glycylcycline for treatment of serious infections

21 January 2018

1 reference

Pharmacokinetic/pharmacodynamic profile for tigecycline-a new glycylcycline antimicrobial agent

21 January 2018

1 reference

In vitro activity of tigecycline against 3989 Gram-negative and Gram-positive clinical isolates from the United States Tigecycline Evaluation and Surveillance Trial (TEST Program; 2004).

21 January 2018

1 reference

In vitro evaluation of tigecycline and comparative agents in 3049 clinical isolates: 2001 to 2002.

21 January 2018

1 reference

Tigecycline activity tested against 26,474 bloodstream infection isolates: a collection from 6 continents

21 January 2018

1 reference

Evaluation of the in vitro activity of NVP-LMB415 against clinical anaerobic isolates with emphasis on the Bacteroides fragilis group.

21 January 2018

1 reference

In vitro activity of linezolid against key gram-positive organisms isolated in the united states: results of the LEADER 2004 surveillance program

21 January 2018

1 reference

In vitro activity of GAR-936 against Chlamydia pneumoniae and Chlamydia trachomatis

21 January 2018

1 reference

Comparison of the in vitro activity of the glycylcycline tigecycline (formerly GAR-936) with those of tetracycline, minocycline, and doxycycline against isolates of nontuberculous mycobacteria

21 January 2018

1 reference

Comparison of tetracycline and tigecycline binding to ribosomes mapped by dimethylsulphate and drug-directed Fe2+ cleavage of 16S rRNA.

21 January 2018

1 reference

Effects of efflux transporter genes on susceptibility of Escherichia coli to tigecycline (GAR-936).

21 January 2018

1 reference

The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam

21 January 2018

1 reference

The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data

21 January 2018

1 reference

Pharmacokinetics of Tigecycline after Single and Multiple Doses in Healthy Subjects

21 January 2018

1 reference

Pharmacokinetics, pharmacodynamics, safety and tolerability of tigecycline

21 January 2018

1 reference

Effects of age and sex on single-dose pharmacokinetics of tigecycline in healthy subjects

21 January 2018

1 reference

Results of a multicenter, randomized, open-label efficacy and safety study of two doses of tigecycline for complicated skin and skin-structure infections in hospitalized patients

21 January 2018

1 reference

Pharmacokinetic profile of tigecycline in serum and skin blister fluid of healthy subjects after multiple intravenous administrations

21 January 2018

1 reference

Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline

21 January 2018

1 reference

Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines

21 January 2018

1 reference

Preclinical pharmacology of GAR-936, a novel glycylcycline antibacterial agent.

21 January 2018

1 reference

In vivo pharmacodynamic activities of two glycylcyclines (GAR-936 and WAY 152,288) against various gram-positive and gram-negative bacteria

21 January 2018

1 reference

Tigecycline: a critical analysis

21 January 2018

1 reference

Tigecycline does not induce proliferation or cytotoxin production by epidemic Clostridium difficile strains in a human gut model.

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1345/APH.1H543

1 reference

3 August 2017

1 reference